Effect of lipopolysaccharide (LPS) priming on Candida -induced acute lung injury (ALI) Source: Eur Respir J 2003; 22: Suppl. 45, 585s Year: 2003
The effect of N-acetylcysteine in the acute lung injury rat model stimulated by LPS endotoxin Source: Annual Congress 2009 - Mechanisms of pulmonary inflammation and fibrosis Year: 2009
A role for PAR1 in lipopolysaccharide induced acute lung injury Source: Annual Congress 2008 - Vascular and interstitial remodelling in chronic lung disease: therapeutic interventions on the horizon Year: 2008
Effects of autophagy on LPS-induced lung inflammation and acute lung injury (ALI) in vitro and in vivo Source: International Congress 2018 – Role of microbial exposure and inflammation in lung injury Year: 2018
The effect of heat co-treatment on acute lung injury of the rat induced by intratracheal lipopolysaccharide Source: Eur Respir J 2002; 20: Suppl. 38, 488s Year: 2002
Post-treatment with the heat shock protein 90 (hsp90) inhibitor, AUY-922, reduces lung hsp90 tyrosine (Y) phosphorylation and pulmonary inflammation in LPS-induced acute lung injury (ALI) in mice Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury Year: 2013
Effects of pendrin inhibitor (PDI_C01) in vitro, and in vivo models of lipopolysaccharide-induced airway inflammation. Source: International Congress 2019 – Biomarkers, laboratory findings and pre-clinical data in acute respiratory failure Year: 2019
Effects of CHF6297, a potent and selective p38a MAPK inhibitor, in murine models of steroid resistant lung inflammation Source: International Congress 2017 – Towards new anti-inflammatory and anti-fibrotic agents Year: 2017
Exposure to LPS induces the upregulation of p38 MAPK in human bronchial epithelium in vivo Source: Eur Respir J 2003; 22: Suppl. 45, 459s Year: 2003
Dipeptide HCH6-1 inhibits neutrophil activation and protects against acute lung injury by blocking FPR1 Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017
The pan janus kinase (JAK) inhibitor KN-002 suppresses inflammatory mediator release from severe asthma bronchial epithelial cells. Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021
Effects of anti-IL17 on acute lung injury induced by LPS in mice Source: International Congress 2017 – Anti-inflammatory and pro-repair mediators in acute lung injury Year: 2017
Hsp90 binding inhibitors improve survival in a murine model of sepsis induced acute lung injury Source: Annual Congress 2006 - Novel pathogenic aspects of acute lung injury and acute respiratory distress syndrome (ARDS) Year: 2006
In vivo imaging of NF-kB pathway in acute lung inflammation mouse model can predict a pharmacological response Source: Annual Congress 2011 - Cell biology of lung disease Year: 2011
TD-0903, an inhaled JAK inhibitor in development for COVID-19, blocks ARDS-relevant hyperinflammation and lung injury in primary human immune and airway epithelial cells Source: Virtual Congress 2021 – Emerging respiratory diseases: state-of-the-art studies of SARS-CoV-2 infection Year: 2021
Kallistatin protects against LPS-induced mouse lung injury Source: Annual Congress 2012 - The many roads to lung injury Year: 2012
Influence of Toll-like receptor 4 (TLR4) on cellular signaling of acute lung injury Source: Eur Respir J 2003; 22: Suppl. 45, 268s Year: 2003
Effect of phosphodiesterase-4 inhibitor on the inflammation, oxidative damage and apoptosis in a saline lavage-induced model of acute lung injury Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control Year: 2018
Roflumilast N-oxide (RNO) increases MAP kinase phosphatase-1 (MKP-1) expression in human lung fibroblasts (HLF) Source: Annual Congress 2010 - Lung cell biology and immunology Year: 2010
Increased expression of p38 MAPK in human bronchial epithelium after lipopolysaccharide exposure Source: Eur Respir J 2005; 25: 797-803 Year: 2005